

## Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline

|                       |                 |
|-----------------------|-----------------|
| <b>Guideline Name</b> | Antineoplastics |
|-----------------------|-----------------|

### 1. Criteria

**Product Name:** Brand Afinitor\*, generic everolimus\*, Alecensa\*, Alunbrig\*, Ayvakit\*, Balversa\*, Bosulif\*, Braftovi\*, Brukinsa\*, Cabometyx\*, Calquence\*, Cometriq\*, Copiktra\*, Cotellic\*, Daurismo\*, Emcyt\*, Erivedge\*, Erleada\*, Farydak\*, Ibrance\*, Iclusig\*, Idhifa\*, Imbruvica\*, Inlyta\*, Inrebic\*, Jakafi\*, Kisqali\*, KISQALI Femara\*, Lenvima\*, Lonsurf\*, Lorbrina\*, Lynparza\*, Mektovi\*, Nerlynx\*, Ninlaro\*, Nubeqa\*, Odomzo\*, Piqray\*, Pomalyst\*, Revlimid\*, Rozlytrek\*, Rubraca\*, Rydapt\*, Stivarga\*, Tagrisso\*, Talzena\*, Tibsovo\*, Turalio\*, Venclexta\*, Verzenio\*, Vitrakvi\*, Vizimpro\*, Xalkori\*, Xospata\*, Xpovio\*, Xtandi\*, Yonsa\*, Zejula\*, Zydelig\*, Brand Zytiga^, generic abiraterone^

|                       |                     |
|-----------------------|---------------------|
| <b>Guideline Type</b> | Prior Authorization |
|-----------------------|---------------------|

#### Approval Criteria

**1** - Prescribed by (or in consultation with) an oncologist, or another appropriate prescriber (e.g., hematologist)

**AND**

**2** - Prescribed for at least ONE of the following:

**2.1** - A Food and Drug Administration (FDA)-approved indication

**OR**

**2.2** - A diagnosis supported by at least ONE of the following:

- National Comprehensive Cancer Network (NCCN) guidelines
- Standard reference compendia (see examples in the Appendix within the Background Section)
- Peer-reviewed published medical literature submitted by the prescriber (see examples in the Appendix within the Background Section)

**AND**

**3** - For brand name requests, trial and failure with OR clinical rationale to avoid use with the therapeutically equivalent generic (if available)

|              |  |
|--------------|--|
| <b>Notes</b> | *Approval Duration: Approve indefinitely (12/31/2039).<br>^Please approve Zytiga & generic abiraterone at GPI List Name HPHCZYTIGA |
|--------------|--|

## 2. Background

### Benefit/Coverage/Program Information

#### **RATIONALE**

To promote the appropriate use of antineoplastic medications based on FDA-approved or NCCN-recognized indications or indications supported by standard reference compendia or peer-reviewed published medical literature.

#### **FDA APPROVED INDICATIONS**

Please refer to the prescribing information for product FDA-approved indications.

#### **REFERENCES**

Please refer to the prescribing information for references.

#### **APPENDIX**

Standard Reference Compendia:

- American Hospital Formulary Service Drug Information (AHFS-DI)
- Drugdex

Centers for Medicare and Medicaid Services (CMS) Recognized Peer-Reviewed Published Medical Literature:

- American Journal of Medicine
- Annals of Internal Medicine
- Annals of Oncology
- Annals of Surgical Oncology
- Biology of Blood and Marrow Transplantation
- Blood
- Bone Marrow Transplantation
- British Journal of Cancer
- British Journal of Hematology
- British Medical Journal
- Cancer
- Clinical Cancer Research
- Drugs
- European Journal of Cancer (formerly the European Journal of Cancer and Clinical Oncology)
- Gynecologic Oncology
- International Journal of Radiation, Oncology, Biology, and Physics
- The Journal of the American Medical Association
- Journal of Clinical Oncology
- Journal of the National Cancer Institute
- Journal of the National Comprehensive Cancer Network (NCCN)
- Journal of Urology
- Lancet
- Lancet Oncology
- Leukemia
- The New England Journal of Medicine
- Radiation Oncology

|  |
|--|
| Created: 07/18   |
| Revised: <ul style="list-style-type: none"><li>• 1/10/20 - Added Nubeqa, Rozlytrek, Inrebic, Turalio (effective: 2/1/20)</li><li>• 2/5/20 - Updated to include generic everolimus (effective: 3/15/20)</li><li>• 3/9/20 - Updated to address brand name requests (requiring step through generic equivalent); Added Ayvakit and Brukinsa</li></ul> |
| P&T Approval: 3/2/20   |
| Effective: 4/1/20  |